New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
14:14 EDTPFE, MKGAYEMD Serono announces FDA approval of Rebif Rebidose
EMD Serono, a subsidiary of Merck KGaA (MKGAY) and Pfizer (PFE), announced earlier today that the FDA approved Rebif Rebidose, a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis. Rebif Rebidose was designed with the objective to assist with ease of use and to offer patients an alternative delivery option. Rebif Rebidose will be available in a monthly pack in two different doses, 22 micrograms and 44 micrograms, and in a titration pack. Rebif Rebidose will be available in the U.S. in early 2013.
News For MKGAY;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 26, 2014
07:48 EDTPFEMylan now most likely takeover target for Pfizer, says Jefferies
Jefferies believes Mylan (MYL), following its combination with Abbott's (ABT) Developed Markets Established Products business, is now the most likely takeover target of Pfizer (PFE). The firm thinks Pfizer management is highly motivated to either merge with, invert into or acquire a foreign company. It believes Actavis (ACT) and AstraZeneca (AZN) are off the table as potential Pfizer targets given the former's takeover of Allergan (AGN) and latter's oncology deal with Merck KGaA (MKGAY). Jefferies calls GlaxoSmithKline (GSK) the "wild card" potential takeover target for Pfizer. The firm estimates Pfizer could pay a 25% premium for Mylan and have the deal be highly accretive.
November 24, 2014
07:46 EDTPFEPfizer seen set to move on from AstraZeneca as restrictions lift, Telegraph says
Subscribe for More Information
November 19, 2014
07:52 EDTPFEInforma Business Information to hold a conference
Subscribe for More Information
November 18, 2014
08:33 EDTPFEPfizer announces availability of Trumenba vaccine
Pfizer announced hat TRUMENBA, the first and only FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age, is now available for order by healthcare providers in the United States.
07:29 EDTMKGAY, PFEPfizer less likely to pursue AstraZeneca after PD-L1 deal, says JPMorgan
Subscribe for More Information
07:18 EDTPFEWoodford confident in Astra, sees 50% chance of new Pfizer bid, Reuters reports
Investment manager Neil Woodford of Woodford Investment Management said he now has an even stronger belief in AstraZeneca (AZN), citing the company's strong product pipeline, and put the chances of a new takeover bid from Pfizer (PFE) at 50/50, reported Reuters, citing a statement from Woodford. Reference Link
06:39 EDTPFEAstraZeneca: 'Hard to comment' on whether Pfizer will come back, Reuters reports
Subscribe for More Information
November 17, 2014
14:27 EDTPFEPfizer volatility flat into investor meeting
Subscribe for More Information
09:42 EDTPFEPfizer to host investor day
Subscribe for More Information
09:22 EDTPFEOn The Fly: Pre-market Movers
Subscribe for More Information
08:13 EDTPFEPortola, Bristol-Myers, Pfizer announce results from Phase 3 ANNEXA-A studies
Subscribe for More Information
07:16 EDTPFEMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
06:43 EDTPFEAstraZeneca, Pfizer deal seen less likely after Merck transaction, Reuters says
Subscribe for More Information
05:27 EDTPFE, MKGAYPfizer lowers FY14 Reported EPS view to $1.40-$1.49 from $1.50-$1.59
Subscribe for More Information
05:23 EDTPFE, MKGAYPfizer forms strategic alliance with Merck KGaA
Subscribe for More Information
November 14, 2014
14:53 EDTPFECVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
10:00 EDTMKGAYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:58 EDTMKGAYMerck KGaA upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill upgraded Merck KGaA (MKGAY) to Neutral citing the contribution from its pending merger with Sigma-Aldrich (SIAL).
07:14 EDTPFEAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
07:38 EDTPFEBloomberg Link to hold a conference
The Year Ahead: 2015 is being held in Washington, D.C. with a pre-conference dinner on November 13 followed by company presentations on November 14,
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use